|
[Related PubMed/MEDLINE]
Total Number of Papers: 650
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: GEJ |
| Long Form |
: gastroesophageal junction |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
Contemporary outcomes of esophageal and gastroesophageal junction neuroendocrine tumors. |
--- |
| 2 |
2023 |
Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study. |
CapeOX, CI, CPS, DCR, EBV, GC, HER2, HR, NLR, ORR, OS, PD-L1, PFS, TRAEs |
| 3 |
2023 |
Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials. |
AEs, ESCC, ICIs, nCRT |
| 4 |
2023 |
Event-free survival as a surrogate for overall survival in gastric and gastroesophageal junction adenocarcinoma: A meta-analysis in the neoadjuvant ±adjuvant setting. |
CI, EFS, HR, OS, RCTs |
| 5 |
2023 |
Evidence-Based Surgical Approach to Gastroesophageal Junction Cancer: How We Do Robotic Transhiatal Lower Mediastinal Dissection and Esophagojejunostomy. |
LN |
| 6 |
2023 |
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. |
AC, CPS, CT, HER2, PD-L1 |
| 7 |
2023 |
Survival after Ivor Lewis versus McKeown esophagectomy for cancer: propensity score matched analysis. |
IL, McK, RS |
| 8 |
2022 |
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. |
ADX, AEs, MMP-9, SOX, SP |
| 9 |
2022 |
A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases. |
OS |
| 10 |
2022 |
A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study. |
AGC, CHT, CRT, EFS, LAGC, ORR, OS, pCR, pPR |
| 11 |
2022 |
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome. |
EGD, MWS |
| 12 |
2022 |
Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection. |
CRT, CT, OS, PSM |
| 13 |
2022 |
Assessment and validation of the internal gross tumour volume of gastroesophageal junction cancer during simultaneous integrated boost radiotherapy. |
4DCT, AP, CBCT, CC, IGTV, LR |
| 14 |
2022 |
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. |
--- |
| 15 |
2022 |
Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol. |
BMI |
| 16 |
2022 |
Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. |
OS, PFS, PS |
| 17 |
2022 |
Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan. |
CPS, EBV, MSI-H, PD-L1 |
| 18 |
2022 |
Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades. |
CI, CRT, CT, ITT, OS, RCTs, RT |
| 19 |
2022 |
Differences in clinicopathology and prognosis between gastroesophageal junctional and gastric non-cardiac neuroendocrine carcinomas: a retrospective comparison study of consecutive 56 cases from a single institution in China. |
MiNEN, NEC |
| 20 |
2022 |
Does radiomics play a role in the diagnosis, staging and re-staging of gastroesophageal junction adenocarcinoma? |
RQS |
| 21 |
2022 |
Does the Computed Tomography Hounsfield Units Change Predict Response to Perioperative Chemotherapy in Patients with Gastric Adenocarcinoma. |
CT, FU, GC, LV |
| 22 |
2022 |
Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report. |
HER2 |
| 23 |
2022 |
Dual-layer dual-energy CT for improving differential diagnosis of squamous cell carcinoma from adenocarcinoma at gastroesophageal junction. |
AC, AP, IC, ROC, SCC, SDCT, VP |
| 24 |
2022 |
Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy. |
DeltaSII, DFS and OS, HR, NACT, SII, TRG |
| 25 |
2022 |
Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. |
CCRT, DFS, EFS, MPR, OS, pCR, PD-1 |
| 26 |
2022 |
Esophagectomy vs Gastrectomy for Early Stage Adenocarcinoma of the Gastroesophageal Junction: What is the Optimal Oncologic Surgical Treatment? |
KM, OS, PSM |
| 27 |
2022 |
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. |
D1D8, EDRs, PFS |
| 28 |
2022 |
Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status. |
GC, TP53 MUT |
| 29 |
2022 |
Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction. |
NCRT, pCR, SCC |
| 30 |
2022 |
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. |
CF, OS, PFS |
| 31 |
2022 |
Gastrectomy for Cancer: A 15-Year Analysis of Real-World Data from the University of Athens. |
DFS, OS |
| 32 |
2022 |
Generation and multiomic profiling of a TP53/CDKN2A double-knockout gastroesophageal junction organoid model. |
CDKN2A, FOXM1, PTAFR, PTAFs, TP53 |
| 33 |
2022 |
Heterotopic Pancreas Located at the Gastroesophageal Junction in a Hiatal Hernia: A Case Report. |
--- |
| 34 |
2022 |
Identification and Somatic Characterization of the Germline PTEN Promoter Variant rs34149102 in a Family with Gastrointestinal and Breast Tumors. |
PHTS |
| 35 |
2022 |
Impedance planimetry (EndoFLIP™) after magnetic sphincter augmentation (LINX®) compared to fundoplication. |
DI, FLIP, LF, MSA, RSI |
| 36 |
2022 |
Impedance planimetry (EndoFLIP™) reveals changes in gastroesophageal junction compliance during fundoplication. |
DI |
| 37 |
2022 |
Intraoperative near-infrared lymphography with indocyanine green may aid lymph node dissection during robot-assisted resection of gastroesophageal junction cancer. |
ICG, IQR, LN, NIR |
| 38 |
2022 |
Is there a role for upper gastrointestinal contrast study to predict the outcomes of sleeve gastrectomy? Lessons learnt from a prospective study. |
GDE, GERD, SG, UGI |
| 39 |
2022 |
Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment? |
AT, cT2N0, NAT |
| 40 |
2022 |
Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. |
CI |
| 41 |
2022 |
Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option? |
CT, NAT, RCT |
| 42 |
2022 |
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. |
dMMR, MSI-H, pCR |
| 43 |
2022 |
Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer. |
AC, SCC |
| 44 |
2022 |
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. |
CPS, EV, OS, PD, PFS, TME |
| 45 |
2022 |
Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer. |
mIF, NGS, pCR, TRAEs, TRG |
| 46 |
2022 |
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). |
FLOT, OS, pCR |
| 47 |
2022 |
Population-Based Cohort Study from a Prospective National Registry: Better Long-Term Survival in Esophageal Cancer After Minimally Invasive Compared with Open Transthoracic Esophagectomy. |
ASA, CI, HMIE, HR, MIE, OE, OR, TMIE |
| 48 |
2022 |
Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. |
CT, HRs, NMA, OS and DFS, SUCRA |
| 49 |
2022 |
Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastroesophageal cancer in a large Belgian cohort. |
GEC, IHC, ISH, MSI, MSI-H, PCR |
| 50 |
2022 |
Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review. |
CI, HR, nCRT, OS, PFS, RCTs |
| 51 |
2022 |
Quantifying physiologic parameters of the gastroesophageal junction during robotic sleeve gastrectomy and identifying predictors of post-sleeve gastroesophageal reflux disease. |
CSA, DI, GERD, LES |
| 52 |
2022 |
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). |
CI, HER2, OS |
| 53 |
2022 |
Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. |
DCR, ORR, OS, PFS |
| 54 |
2022 |
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. |
DCR, ORR, OS, PFS |
| 55 |
2022 |
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. |
DFS, GC, NACT, OS, pCR |
| 56 |
2022 |
Reconstruction of the Gastro-esophageal Junction Based on Ultramill Imaging for Biomechanical Analysis. |
--- |
| 57 |
2022 |
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma. |
GC, mDCF, mOS, mPFS |
| 58 |
2022 |
Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial. |
DFS, GC, OS |
| 59 |
2022 |
Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials. |
NSCLC, TEAEs |
| 60 |
2022 |
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. |
DLTs, HER2, MMP-9, PD-1, PK |
| 61 |
2022 |
Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. |
AEs, ICI |
| 62 |
2022 |
Severe Gastric Mucosal Necrosis Due to Giant Paraesophageal Hernia. |
PEH |
| 63 |
2022 |
Surgical pathology of adenocarcinomas arising around or within the gastroesophageal junction. |
AC, IHC |
| 64 |
2022 |
The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer. |
AEs, CR, DCR, GC, HER2, irAEs, ORR, PD, PFS, PR, SD |
| 65 |
2022 |
The impact of hiatal hernia on survival outcomes in patients with gastroesophageal junction adenocarcinoma. |
HH, OS, RFS |
| 66 |
2022 |
The role of proximal gastrectomy in gastric cancer. |
GC, PG |
| 67 |
2022 |
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. |
HER2 |
| 68 |
2022 |
Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States. |
HHI, NCCN, OS, US |
| 69 |
2022 |
Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. |
--- |
| 70 |
2022 |
Tubularized and Effaced Gastric Cardia Mimicking Barrett Esophagus Following Sleeve Gastrectomy: Protocolized Endoscopic and Histological Assessment With High-resolution Manometry Analysis. |
BE, HRM |
| 71 |
2022 |
Type II hiatal hernias: do they exist or are they actually parahiatal hernias? |
HH, PEH |
| 72 |
2022 |
Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time? |
AJCC, DSS, MSK |
| 73 |
2022 |
Video-assisted thoracoscopic surgery (VATS) enucleation of large gastroesophageal junction leiomyoma: A case report. |
CT, EUS, VATS |
| 74 |
2022 |
[THE MAGIC OF IMMUNOTHERAPY - ANTI-PD1 TREATMENT IN ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION]. |
--- |
| 75 |
2022 |
[UPPER GASTROINTESTINAL BLEEDING CAUSED BY BREAST ANGIOSARCOMA METASTASIS LOCATED IN THE GASTRO-ESOPHAGEAL JUNCTION]. |
GI |
| 76 |
2021 |
A Patient-Derived Orthotopic Xenograft Model of Gastroesophageal-Junction Adenocarcinoma Translated to the Clinic by Tumor-Targeting Fluorescent Antibodies to Carcinoembryonic-Antigen-Related Cell-Adhesion Molecules. |
PDOX |
| 77 |
2021 |
A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. |
AC, CRT, pCR, RFS |
| 78 |
2021 |
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy. |
ERCP, EUS |
| 79 |
2021 |
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature. |
--- |
| 80 |
2021 |
Autophagic Heterogeneity in Gastric Adenocarcinoma. |
--- |
| 81 |
2021 |
Back to the future: laparoscopic transgastric resection of a subepithelial tumor in the gastroesophageal junction |
--- |
| 82 |
2021 |
Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). |
GAIN |
| 83 |
2021 |
Blastic Mantle Cell Lymphoma of the Gastroesophageal Junction: A Unique Presentation and Literature Review. |
EGDs, IHC, MCL |
| 84 |
2021 |
Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis. |
GC, IHC, ISH, LapChemo, OS, PerTraChemo, RCTs, TraChemo, TraD |
| 85 |
2021 |
Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis. |
AEs, AGC, CrI, DCR, HR, ICIs, mOS, mPFS, NMA, POS, PPFS, RCTs |
| 86 |
2021 |
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]. |
--- |
| 87 |
2021 |
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece. |
BSC, ICER, LYs, MGC, QALYs |
| 88 |
2021 |
CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer. |
ADC, CROSS, FLOT, SCC |
| 89 |
2021 |
Distinct Differences in Gastroesophageal Junction and Gastric Adenocarcinoma in 2194 Patients: In Memory of Rebecca A. Carr, February 24, 1988-January 19, 2021. |
DSS, GC |
| 90 |
2021 |
Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis. |
CROSS, DFS, EAC, OS, SCCs |
| 91 |
2021 |
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. |
HR |
| 92 |
2021 |
Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma: An Ongoing Debate. |
--- |
| 93 |
2021 |
Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis. |
CI, HR, NCDB, PSM |
| 94 |
2021 |
Evolving treatment paradigms in esophageal cancer. |
SCC |
| 95 |
2021 |
Genomic Heterogeneity and Clonal Evolution in Gastroesophageal Junction Cancer Revealed by Single Cell DNA Sequencing. |
CNVs, MALBAC, SNVs |
| 96 |
2021 |
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. |
HER2 |
| 97 |
2021 |
Identification of Barrett's esophagus in endoscopic images using deep learning. |
BE, FCN, IoU, SCJ |
| 98 |
2021 |
Immunotherapy in esophagogastric cancer. |
MSI |
| 99 |
2021 |
Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. |
IC, NCDB, nCRT, OS, pCR |
| 100 |
2021 |
Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India. |
EC, nCRT, NCT |
|
A Search Service for Abbreviation / Long Form
